Dette er gældende for patienter med nyligt diagnosticeret glioblastom multiforme, der behandles i kombination med strålebehandling, eller som behandles med monoterapi efterfulgt af strålebehandling, samt for patienter med recidiv eller progressivt gliom, der behandles med monoterapi.
In patients treated with TMZ, whether used in combination with RT or as monotherapy following RT for newly-diagnosed glioblastoma multiforme, or as monotherapy in patients with recurrent or progressive glioma, the reported very common adverse reactions were similar: nausea, vomiting, constipation, anorexia, headache and fatigue.